Results 171 to 180 of about 243,754 (245)

Serum and urine anti-PLA2R antibody correlation with albuminuria in idiopathic membranous nephropathy. [PDF]

Front Immunol
Liu X, Fu Y, Sui M, Wang X, Li Z.
europepmc   +1 more source

Correction: Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study. [PDF]

Front Immunol
Frontiers Production Office .
europepmc   +1 more source

Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles. [PDF]

J Am Soc Nephrol
Liu Y, Chen P, Chen G, Hong J, Zhou Y, Zheng K, Ai S, Ai S, Gao Z, Xia P, Cui H, Wang R, Shi X, Li X, Li X, Zhang L, Qin Y.   +16 more
europepmc   +1 more source

Urinary betaine/creatinine ratio enhances diagnostic accuracy of PLA2R-Ab in idiopathic membranous nephropathy. [PDF]

BMC Nephrol
Wang J, Shao L, Lin B, Xi Y, Jiang Y, Qin X.   +5 more
europepmc   +1 more source

Chapter 7: Idiopathic membranous nephropathy [PDF]

Kidney International Supplements, 2012
openaire   +2 more sources

First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study. [PDF]

Kidney Med
Wang L, Yang M, Yan L, Shao F.
europepmc   +1 more source

SPP1 as a biomarker for idiopathic membranous nephropathy progression and its regulatory role in inflammation and fibrosis. [PDF]

Front Immunol
Pang S, Zhou R, Liu Z, Xie B, Liu F, Feng B, Chen X, Ruan L, Chen H, Xie Y, Tan Q, Zhao B, Li S, Xue C, Yang R, Li W.   +15 more
europepmc   +1 more source

re Steroids in the Treatment of Idiopathic Membranous Nephropathy [PDF]

Nephron, 2008
openaire   +2 more sources

Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Liu Y, Lu K.
europepmc   +1 more source

Exploring the mechanism of Kemofang in treating idiopathic membranous nephropathy based on LC-MS/MS combined with network pharmacology, molecular docking, and molecular dynamics simulation. [PDF]

Sci Rep
Yu H, Li F, Yu H, Jiang X, Ma S, Zhang S.   +5 more
europepmc   +1 more source